Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

16 Dec 2009
Membership of Board Committees

December 16, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the Board has appointed Mr David Stout as a member of the Audit, Compliance & Risk Committee with effect from December 8, 2009.

Tony Guthrie
Deputy Secretary

 

For further information please contact:

Investor Relations

Cléa Rosenfeld (Rest of the World)

+44 1256 894 160

 

Eric Rojas (North America)

+1 617 551 9715

  
Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

16 Dec 2009 Membership of Board Committees (15KB PDF)

« Back to Shire news

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device
.